SynthesisThoracic cancer2025
A Comprehensive Study on Clinical Outcomes and Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Limited-Stage Small Cell Lung Cancer.
Synthesis in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Comprehensive Study on Clinical Outcomes and Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Limited-Stage Small Cell Lung Cancer.Thoracic cancer · 2025Pooled it
- Surgery versus radiotherapy after neoadjuvant immunochemotherapy in limited-stage small cell lung cancer.Journal of thoracic disease · 2026Article
- Digital immune twins and ai-integrated multi-omic biomarkers: Redefining personalized immunotherapy in non-small cell lung cancer.Iranian journal of basic medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aims to explore clinical outcomes and safety of neoadjuvant immunotherapy combined with chemotherapy in limited-stage small cell lung cancer (SCLC), providing insights for upcoming clinical trials.
methodsPubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched for relevant original articles and conference proceedings, updated through 10 February 2025. Pathological complete response (pCR) rate and major pathological response (MPR) rate were calculated as the major assessments for the clinical outcomes. The incidences of the rate of R0 resection and treatment-related severe adverse events (tr-SAE) were considered as the primary outcomes for assessing the safety. Subgroup analyses were conducted according to neoadjuvant therapy cycle and study type.
resultsA total of 114 patients from 6 studies were included. The meta-analysis results suggested that the pooled rates of pCR and MPR were 35% [95% confidence interval (CI) 14-56] and 49% (95% CI 18-80) in LS-SCLC patients. In terms of safety, most patients achieved R0 surgical resection [95% (95% CI 85-100)] and the pooled incidence of tr-SAE was 44% (95% CI 13-76). Meanwhile, all studies reported that there were no deaths during the perioperative period. Subgroup analysis suggests that more than two neoadjuvant therapy cycles may be associated with better clinical outcomes.
conclusionsIn conclusion, the current research findings demonstrate that neoadjuvant immunotherapy has shown promising clinical efficacy and acceptable safety in SCLC. These results provide valuable reference for upcoming clinical trials regarding the optimal neoadjuvant strategy and potential beneficiary populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.